Ziconotide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store unopened vials refrigerated at 2-8 degrees C, protected from light. Do not freeze. When using external microinfusion devices, diluted solution should be replaced every 24 hours. When using implanted pumps, the infusion may be used for up to 60 days at 37 degrees C body temperature.
Protocol Quick-Reference
Severe chronic pain management (intrathecal)
Dosing
Amount
2.4-19.2 mcg/day (0.1-0.8 mcg/hour)
Frequency
Continuous intrathecal infusion
Duration
Long-term continuous therapy
Administration
Route
IVSchedule
Continuous intrathecal infusion via implanted pump
Timing
Start at 2.4 mcg/day (0.1 mcg/hour). Titrate upward by no more than 2.4 mcg/day at intervals of no more than 2-3 times per week. Slow titration is critical for tolerability.
Cycle
Duration
Ongoing
Repeatable
Yes
โ๏ธ Suggested Bloodwork (3 tests)
Serum creatine kinase (CK)
When: Baseline and periodic
Why: Monitor for CK elevation (common with ziconotide)
Neuropsychiatric assessment
When: Baseline and ongoing
Why: Monitor for psychiatric symptoms including psychosis and suicidal ideation (black box warning)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Liver and kidney function baseline
๐ก Key Considerations
- โBlack box warning for severe psychiatric symptoms including psychosis, hallucinations, and suicidal ideation
- โMust be administered exclusively by intrathecal infusion via implanted pump or external device by experienced pain physicians
- โContraindicated in patients with a history of psychosis; CNS adverse effects are dose-related and improve with slow titration
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| FDA-approved intrathecal infusion for severe chronic pain | Initial: 2.4 mcg/day (0.1 mcg/hour). Maximum: 19.2 mcg/day (0.8 mcg/hour) | Continuous intrathecal infusion | Long-term continuous therapy | Titrate upward by no more than 2.4 mcg/day (0.1 mcg/hour) at intervals of no more than 2-3 times per week. Slow titration improves tolerability. Dose adjustments should be based on pain relief and adverse effects. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Prialt (ziconotide intrathecal infusion) is supplied as a preservative-free solution at 25 mcg/mL or 100 mcg/mL. For external microinfusion devices, dilute to 25 mcg/mL with preservative-free 0.9% sodium chloride. For implanted programmable pumps (e.g., SynchroMed), the undiluted 100 mcg/mL concentration may be used.
Recommended Injection Sites
- โIntrathecal (lumbar level via implanted pump or external device)
๐งStorage Requirements
Store unopened vials refrigerated at 2-8 degrees C, protected from light. Do not freeze. When using external microinfusion devices, diluted solution should be replaced every 24 hours. When using implanted pumps, the infusion may be used for up to 60 days at 37 degrees C body temperature.
Community Dosing Protocols
Compare these clinical doses with what 30+ community members report using.
Based on 30+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
Ziconotide (Prialt) is an FDA-approved prescription medication that must be administered exclusively by intrathecal infusion. It requires implantation of a drug delivery system and management by physicians experienced in intrathecal therapy. This information is for educational purposes.
FDA-Approved Dosing#
Initial Dose#
The recommended starting dose is 2.4 mcg/day (0.1 mcg/hour) delivered by continuous intrathecal infusion. Starting at this low dose and titrating slowly is critical for tolerability.
Titration#
Dose increases should be no more than 2.4 mcg/day (0.1 mcg/hour) at intervals no more frequent than 2-3 times per week, up to a maximum recommended dose of 19.2 mcg/day (0.8 mcg/hour) by Day 21. In clinical practice, the effective maintenance dose is typically much lower than the maximum. The Rauck 2006 trial demonstrated that slow titration (mean final dose 6.96 mcg/day) resulted in better tolerability than earlier trials with faster titration.
Maximum Dose#
The maximum recommended dose is 19.2 mcg/day (0.8 mcg/hour). In clinical trials, higher doses were associated with significantly more adverse events without proportional improvement in pain relief.
Route of Administration#
Ziconotide is administered exclusively via the intrathecal route using either an implanted programmable microinfusion pump (e.g., Medtronic SynchroMed) or an external microinfusion device with catheter. Systemic administration is not effective due to the peptide's inability to cross the blood-brain barrier.
Reconstitution and Preparation#
Prialt is supplied as a clear, colorless, preservative-free solution in two concentrations: 25 mcg/mL (20 mL vials) and 100 mcg/mL (1 mL, 2 mL, and 5 mL vials). For external devices, dilute with preservative-free normal saline to a final concentration of 25 mcg/mL using aseptic technique.
Storage Guidelines#
Store unopened vials refrigerated at 2-8 degrees C and protect from light. Do not freeze. Once prepared for infusion, the solution should be used within 24 hours for external devices. In implanted pumps at body temperature, the solution remains stable for up to 60 days.
Dosing Context#
Ziconotide belongs to the Pain category of research peptides. Dosing protocols for Ziconotide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Ziconotide:
FDA-approved intrathecal infusion for severe chronic pain#
Dose: Initial: 2.4 mcg/day (0.1 mcg/hour). Maximum: 19.2 mcg/day (0.8 mcg/hour)
Frequency: Continuous intrathecal infusion
Duration: Long-term continuous therapy
Titrate upward by no more than 2.4 mcg/day (0.1 mcg/hour) at intervals of no more than 2-3 times per week. Slow titration improves tolerability. Dose adjustments should be based on pain relief and adverse effects.
Reconstitution and Preparation#
Prialt (ziconotide intrathecal infusion) is supplied as a preservative-free solution at 25 mcg/mL or 100 mcg/mL. For external microinfusion devices, dilute to 25 mcg/mL with preservative-free 0.9% sodium chloride. For implanted programmable pumps (e.g., SynchroMed), the undiluted 100 mcg/mL concentration may be used.
Injection Sites#
Recommended injection sites for Ziconotide include:
- Intrathecal (lumbar level via implanted pump or external device)
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Store unopened vials refrigerated at 2-8 degrees C, protected from light. Do not freeze. When using external microinfusion devices, diluted solution should be replaced every 24 hours. When using implanted pumps, the infusion may be used for up to 60 days at 37 degrees C body temperature.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Ziconotide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.